Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

About this update from Hemostemix Inc

[{"type":"text","content":"Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First TwoCalgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemix for 2,000,000 shares each, subject to adjustment and TSXV approval. This marks the first of many acquisitions, as Hemostemix's long-term strategy to acquire profitable, accretive medical practices within which is can add ACP-01 treatments. Capable of generating a sustainable, predictable commercial stream of patients for treatment with ACP-01, the Company's operations strategy will focus on patient treatment flow, while the Company's sales team focus on leveraging the practitioner to practitioner dialogue to increase the number of practitioners treating with ACP-01 (patient volumes). Two cardiologists with more than 200 ACP-01 patient treatmentsCombined, Dr. Fernandez-de-Castro and Dr. Rosario Figueroa have treated more than 200 patients with ACP-01, making them among the most experienced ACP-01 clinicians globally. Given their track record as pioneers in the safe treatment of end-stage no option CVD patients, Dr. Fernandez de Castro and Dr. Rosario Figueroa have the credibly to attest to the safety, feasibility, clinical relevancy and observed efficacy of ACP-01 to patients, referring physicians, hospital partners, and regulators.Their experience spans multiple indications, including:AnginaIschemic and Dilated CardiomyopathyCongestive Heart FailurePeripheral Arterial DiseaseChronic Limb-Threatening IschemiaVascular Dementia.Their clinical expertise, long-standing patient bases, and reputations within the Dominican Republic's medical community position them as ideal anchor practices for Hemostemix's first international clinical and commercial footprint.Under the terms of the LOI, Dr. Roberto Fernandez-de-Castro and Dr. Rosario Figueroa: Will each contribute his medical expertise and experience in cardiovascular disease treatments of Angina, Ischemic and Dilated Cardiomyop...

More updates from Hemostemix Inc